3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 1
1
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
3
Neoplasm Metastasis
2
Rheumatoid Arthritis, Systemic Juvenile
1
Periodic Fevers Syndrome
1
Mevalonate Kinase Deficiency
1
Lung Neoplasms
1
Cryopyrin-Associated Periodic Syndromes
1
Carcinoma
1
Bronchiolitis Obliterans Syndrome
1
Arthritis, Juvenile
1
Arthralgia
1
Interventions
Leucovorin
22
Fluorouracil
22
Paclitaxel
21
Gemcitabine
21
Docetaxel
21
Capecitabine
21
Irinotecan
16
Carboplatin
15
Radiosurgery
14
Oxaliplatin
13
Cisplatin
13
Bevacizumab
13
Zoledronic Acid
12
pembrolizumab
11
Radiotherapy
11
Fulvestrant
11
palbociclib
9
Pemetrexed
9
Drug Therapy
9
130-nm albumin-bound paclitaxel
9
Surgical Procedures, Operative
7
Letrozole
7
Ibandronic Acid
7
abemaciclib
6
Trastuzumab
6
Prednisone
6
Vinorelbine
5
Folfox protocol
5
Floxuridine
5
Doxorubicin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasm Metastasis
×
canakinumab
×
Clear all
NCT03631199
2026-02-25
CANOPY-1
Novartis
Phase 3
Terminated
673 enrolled
38 charts
NCT03626545
2023-08-21
CANOPY-2
Novartis
Phase 3
Terminated
245 enrolled
29 charts